v3.26.1
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income $ 5,290 $ 6,089
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 421 405
Amortization 478 1,048
Provision for (recovery of) losses on accounts receivable (12) (7)
Amortization of Right-of-Use Assets 30 26
Deferred income taxes (178) (360)
Stock-based compensation expense 192 168
Tax benefit attributable to exercise of stock options 0 0
Accounts receivable and other receivables (56) 409
Inventories (1,130) 908
Prepaid expenses and other current assets (22) 145
Accounts payable (34) 37
Accrued expenses (487) (1,531)
Total adjustments (798) 1,248
Net cash provided by operating activities 4,492 7,337
CASH FLOWS FROM INVESTING ACTIVITIES    
Property and equipment (264) (235)
Net cash used in investing activities (264) (235)
CASH FLOWS FROM FINANCING ACTIVITIES    
Common stock purchased and retired (206) (6,708)
Payment of dividends (1,976) (2,018)
Net cash used in financing activities (2,182) (8,726)
Effect of exchange rate changes on cash (274) 827
Net increase/(decrease) in cash and cash equivalents 1,772 (797)
Cash at beginning of period 85,756 82,976
Cash at end of period 87,528 82,179
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION    
Cash paid during the period for income taxes 1,660 2,327
Cash paid during the period for interest $ 0 $ 0